sucralfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4106 54182-58-0

Description:

MoleculeDescription

Synonyms:

  • sucralfate
  • antepsin
  • carafate
  • sucralfin
  • sucrate
  • sulcrate
  • ulcerlmin
  • ulcogant
A basic aluminum complex of sulfated sucrose.
  • Molecular weight:
  • Formula: None
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
4 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 30, 1981 FDA FOREST LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vaginal flatulence 119.24 12.00 48 29280 3245 63456449
Proctitis 108.10 12.00 52 29276 5389 63454305
Female genital tract fistula 94.69 12.00 53 29275 7506 63452188
Radiculopathy 88.27 12.00 53 29275 8558 63451136
Vaginal discharge 80.03 12.00 51 29277 9147 63450547
Maternal exposure during pregnancy 78.83 12.00 6 29322 220056 63239638
Drug ineffective 73.18 12.00 244 29084 1044521 62415173
Contraindicated product administered 72.44 12.00 8 29320 217640 63242054
Abdominal pain 66.51 12.00 290 29038 293166 63166528
Cholecystitis chronic 65.18 12.00 47 29281 10314 63449380
Frequent bowel movements 65.17 12.00 66 29262 22956 63436738
Gastritis 63.22 12.00 82 29246 37221 63422473
Hand deformity 61.14 12.00 3 29325 159454 63300240
Colitis ulcerative 56.63 12.00 65 29263 26026 63433668
Joint swelling 55.72 12.00 42 29286 327624 63132070
Oral candidiasis 53.24 12.00 59 29269 22739 63436955
Colitis 52.12 12.00 86 29242 48442 63411252
Glossodynia 51.60 12.00 10 29318 178866 63280828
Nausea 50.61 12.00 609 28719 853862 62605832
Angina bullosa haemorrhagica 50.41 12.00 12 29316 132 63459562
Systemic lupus erythematosus 50.10 12.00 17 29311 208901 63250793
Pericarditis 48.81 12.00 3 29325 131576 63328118
Toxicity to various agents 46.98 12.00 28 29300 247222 63212472
Oesophagitis 46.13 12.00 45 29283 14963 63444731
Treatment failure 44.68 12.00 18 29310 199025 63260669
Constipation 44.00 12.00 213 29115 224730 63234964
Gastric ulcer 40.97 12.00 53 29275 23984 63435710
Exposure during pregnancy 40.27 12.00 11 29317 155536 63304158
Early satiety 37.73 12.00 15 29313 981 63458713
Rectal haemorrhage 37.50 12.00 75 29253 48955 63410739
Facial asymmetry 37.17 12.00 14 29314 791 63458903
Muscle swelling 35.97 12.00 12 29316 474 63459220
Impaired gastric emptying 35.60 12.00 33 29295 10299 63449395
Product use issue 34.07 12.00 31 29297 220489 63239205
Gastrooesophageal reflux disease 33.69 12.00 109 29219 95530 63364164
Rheumatoid arthritis 33.27 12.00 41 29287 253778 63205916
Wound 33.15 12.00 17 29311 163246 63296448
Abdominal pain upper 33.09 12.00 185 29143 206259 63253435
Lower respiratory tract infection 33.06 12.00 10 29318 132297 63327397
Dehydration 33.05 12.00 163 29165 173191 63286503
Haematochezia 32.98 12.00 75 29253 53469 63406225
Drug intolerance 32.54 12.00 58 29270 308603 63151091
Weight decreased 32.49 12.00 229 29099 276569 63183125
Musculoskeletal stiffness 32.21 12.00 23 29305 184595 63275099
Hepatic enzyme increased 30.60 12.00 29 29299 202299 63257395
Vulval disorder 29.14 12.00 12 29316 860 63458834
General physical health deterioration 28.03 12.00 31 29297 201371 63258323
Cholelithiasis 27.57 12.00 62 29266 43863 63415831
Gastrointestinal haemorrhage 27.23 12.00 91 29237 81085 63378609
Product dose omission issue 26.98 12.00 193 29135 234120 63225574
Completed suicide 26.95 12.00 17 29311 145656 63314038
Tarsal tunnel syndrome 26.57 12.00 10 29318 564 63459130
Therapeutic product effect decreased 24.48 12.00 32 29296 193155 63266539
Urinary tract infection 24.38 12.00 207 29121 264477 63195217
Alopecia 24.00 12.00 78 29250 337458 63122236
Intentional overdose 23.97 12.00 3 29325 74149 63385545
Arthropathy 23.94 12.00 45 29283 234747 63224947
Gallbladder disorder 23.83 12.00 36 29292 18806 63440888
Helicobacter infection 23.20 12.00 7 29321 92778 63366916
Discomfort 23.03 12.00 26 29302 167348 63292346
Anaemia 22.71 12.00 221 29107 293209 63166485
Haematemesis 22.63 12.00 46 29282 30366 63429328
Diarrhoea 22.56 12.00 459 28869 714907 62744787
Paranoia 21.88 12.00 27 29301 11652 63448042
Genotype drug resistance test positive 21.71 12.00 8 29320 425 63459269
Cellulitis 21.64 12.00 85 29243 81873 63377821
Vascular rupture 21.51 12.00 12 29316 1688 63458006
Haemoglobin decreased 21.09 12.00 127 29201 145358 63314336
Oesophageal stenosis 20.96 12.00 15 29313 3251 63456443
External ear cellulitis 20.83 12.00 7 29321 283 63459411
Blister 20.34 12.00 18 29310 129796 63329898
Movement disorder 20.11 12.00 36 29292 21625 63438069
Purpura senile 19.67 12.00 8 29320 555 63459139
Vomiting 19.62 12.00 365 28963 559252 62900442
Drug abuse 19.00 12.00 5 29323 72513 63387181
Faeces discoloured 18.79 12.00 32 29296 18477 63441217
Off label use 18.50 12.00 211 29117 674251 62785443
Chronic sinusitis 18.36 12.00 26 29302 12817 63446877
Liver abscess 18.07 12.00 13 29315 2841 63456853
Procedural pain 17.71 12.00 34 29294 21535 63438159
Blood alkaline phosphatase increased 16.99 12.00 51 29277 42916 63416778
Hallucination, auditory 16.93 12.00 25 29303 12799 63446895
Migraine 16.79 12.00 93 29235 103253 63356441
Peptic ulcer 16.48 12.00 15 29313 4572 63455122
Blood magnesium decreased 16.38 12.00 25 29303 13173 63446521
Biliary dyskinesia 16.30 12.00 12 29316 2717 63456977
Pancreatic enzyme abnormality 15.89 12.00 3 29325 9 63459685
Pancreatitis 15.57 12.00 54 29274 49001 63410693
Upper respiratory tract infection 15.51 12.00 77 29251 81970 63377724
Hiatus hernia 15.28 12.00 32 29296 21562 63438132
Gallbladder injury 15.21 12.00 9 29319 1414 63458280
Vestibular disorder 15.16 12.00 9 29319 1422 63458272
Swelling 14.86 12.00 71 29257 275307 63184387
Dyspepsia 14.67 12.00 89 29239 102107 63357587
Dysphagia 14.58 12.00 80 29248 88505 63371189
Flatulence 14.50 12.00 42 29286 34660 63425034
Rash 14.01 12.00 179 29149 560692 62899002
Gastric haemorrhage 13.98 12.00 16 29312 6382 63453312
Psoriatic arthropathy 13.96 12.00 13 29315 91507 63368187
Blood pressure diastolic increased 13.92 12.00 20 29308 9990 63449704
Resorption bone increased 13.47 12.00 8 29320 1266 63458428
Suture insertion 13.35 12.00 5 29323 278 63459416
Hypersensitivity 13.28 12.00 80 29248 292605 63167089
Impaired healing 12.96 12.00 17 29311 102525 63357169
Oesophageal ulcer 12.94 12.00 13 29315 4477 63455217
Obstruction 12.78 12.00 11 29317 3116 63456578
Ocular neoplasm 12.71 12.00 5 29323 318 63459376
Overdose 12.67 12.00 21 29307 115057 63344637
Limb mass 12.46 12.00 11 29317 3221 63456473
Burning sensation 12.45 12.00 54 29274 54353 63405341
Drug interaction 12.40 12.00 59 29269 229072 63230622
Thiopurine methyltransferase decreased 12.36 12.00 5 29323 342 63459352
Depression 12.36 12.00 142 29186 196350 63263344
Lip ulceration 12.21 12.00 9 29319 2041 63457653

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gastrointestinal haemorrhage 47.04 11.95 106 13645 88371 34854809
Blood aluminium increased 38.62 11.95 6 13745 3 34943177
Gastrooesophageal reflux disease 34.39 11.95 57 13694 37867 34905313
Oesophagitis 31.29 11.95 32 13719 13229 34929951
Asthma-chronic obstructive pulmonary disease overlap syndrome 23.38 11.95 11 13740 1276 34941904
Dysphagia 22.92 11.95 65 13686 62316 34880864
Brugada syndrome 21.49 11.95 9 13742 792 34942388
Completed suicide 21.48 11.95 6 13745 98162 34845018
Vomiting 20.61 11.95 167 13584 247454 34695726
Gastric mucosal calcinosis 20.52 11.95 3 13748 0 34943180
Nausea 19.19 11.95 211 13540 339697 34603483
Toxicity to various agents 18.97 11.95 31 13720 200331 34742849
Blood immunoglobulin E increased 18.81 11.95 12 13739 2534 34940646
Decreased appetite 18.30 11.95 120 13631 166272 34776908
Oesophageal ulcer 17.97 11.95 13 13738 3368 34939812
Mucosal erosion 17.79 11.95 8 13743 836 34942344
Hypogonadism 17.59 11.95 11 13740 2244 34940936
Pneumonia 17.32 11.95 218 13533 362409 34580771
Off label use 17.19 11.95 96 13655 419428 34523752
Sputum increased 17.08 11.95 11 13740 2359 34940821
COVID-19 treatment 14.22 11.95 5 13746 273 34942907
Dehydration 13.83 11.95 93 13658 129876 34813304
Fatigue 13.70 11.95 213 13538 370440 34572740
Ulcer haemorrhage 13.59 11.95 10 13741 2660 34940520
Product use in unapproved indication 13.28 11.95 16 13735 117483 34825697
Dyspepsia 13.21 11.95 38 13713 36694 34906486
Gastrointestinal pain 13.13 11.95 11 13740 3531 34939649
Enterococcus test positive 13.11 11.95 7 13744 1062 34942118
Muscle twitching 12.90 11.95 18 13733 10280 34932900
Drug abuse 12.87 11.95 12 13739 99084 34844096
Joint dislocation reduction 12.42 11.95 3 13748 42 34943138
Drug ineffective 12.20 11.95 118 13633 456633 34486547
Adenocarcinoma gastric 12.17 11.95 7 13744 1226 34941954
Abdominal pain upper 12.14 11.95 58 13693 71432 34871748

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 61.70 11.18 52 33474 421488 79289374
Oesophagitis 58.28 11.18 61 33465 24228 79686634
Gastrointestinal haemorrhage 57.51 11.18 164 33362 147555 79563307
Cholecystitis chronic 54.67 11.18 40 33486 9866 79700996
Nausea 52.44 11.18 623 32903 956573 78754289
Gastritis 50.43 11.18 80 33446 47913 79662949
Completed suicide 48.97 11.18 21 33505 245746 79465116
Gastrooesophageal reflux disease 48.89 11.18 124 33402 104122 79606740
Abdominal pain 47.48 11.18 303 33223 389266 79321596
Vaginal flatulence 45.35 11.18 22 33504 2553 79708309
Drug ineffective 44.91 11.18 269 33257 1080644 78630218
Blood aluminium increased 43.09 11.18 7 33519 6 79710856
Proctitis 42.52 11.18 29 33497 6403 79704459
Contraindicated product administered 41.37 11.18 8 33518 157530 79553332
Female genital tract fistula 39.64 11.18 27 33499 5948 79704914
Impaired gastric emptying 38.21 11.18 33 33493 10320 79700542
Maternal exposure during pregnancy 37.89 11.18 6 33520 136532 79574330
Angina bullosa haemorrhagica 36.88 11.18 10 33516 211 79710651
Drug abuse 33.86 11.18 13 33513 162678 79548184
Early satiety 33.77 11.18 15 33511 1424 79709438
Vomiting 33.56 11.18 427 33099 665401 79045461
Pericarditis 32.80 11.18 3 33523 104233 79606629
Hand deformity 32.68 11.18 3 33523 103916 79606946
Abdominal pain upper 32.27 11.18 182 33344 223637 79487225
Vaginal discharge 32.13 11.18 26 33500 7437 79703425
Joint swelling 31.80 11.18 45 33481 288601 79422261
Facial asymmetry 30.86 11.18 12 33514 814 79710048
Off label use 30.54 11.18 240 33286 906975 78803887
Haemoglobin decreased 29.03 11.18 176 33350 221943 79488919
Constipation 28.40 11.18 210 33316 282840 79428022
Radiculopathy 28.34 11.18 26 33500 8798 79702064
Overdose 27.80 11.18 22 33504 184184 79526678
Dehydration 27.14 11.18 188 33338 247999 79462863
Gastric ulcer 27.02 11.18 50 33476 33855 79677007
Vulval disorder 26.77 11.18 10 33516 608 79710254
Dysphagia 26.75 11.18 112 33414 122024 79588838
Systemic lupus erythematosus 26.36 11.18 9 33517 121140 79589722
Colitis 25.28 11.18 78 33448 73229 79637633
Oesophageal ulcer 25.27 11.18 22 33504 6953 79703909
Oesophageal stenosis 24.98 11.18 18 33508 4336 79706526
Drug intolerance 24.57 11.18 46 33480 264073 79446789
Frequent bowel movements 24.09 11.18 44 33482 29495 79681367
Cholelithiasis 24.01 11.18 62 33464 52602 79658260
Weight decreased 23.81 11.18 241 33285 354957 79355905
Muscle swelling 23.73 11.18 10 33516 835 79710027
Procedural pain 23.59 11.18 38 33488 23046 79687816
Haematemesis 23.28 11.18 61 33465 52203 79658659
Exposure during pregnancy 22.91 11.18 7 33519 101125 79609737
Intentional overdose 22.83 11.18 8 33518 105952 79604910
Oral candidiasis 22.75 11.18 43 33483 29585 79681277
Ulcer haemorrhage 22.34 11.18 19 33507 5819 79705043
Dyspepsia 21.75 11.18 97 33429 108590 79602272
Treatment failure 21.45 11.18 24 33502 170462 79540400
Macular degeneration 21.28 11.18 25 33501 11271 79699591
Purpura senile 20.87 11.18 8 33518 522 79710340
Tarsal tunnel syndrome 20.78 11.18 8 33518 528 79710334
Product dose omission issue 20.10 11.18 175 33351 247362 79463500
Lower respiratory tract infection 20.05 11.18 15 33511 129205 79581657
Product use issue 19.99 11.18 36 33490 209786 79501076
General physical health deterioration 19.86 11.18 55 33471 275183 79435679
Diarrhoea 19.54 11.18 496 33030 879993 78830869
Hypogonadism 19.43 11.18 11 33515 1749 79709113
Gastrointestinal pain 18.88 11.18 22 33504 9833 79701029
Glossodynia 18.77 11.18 10 33516 103327 79607535
Gallbladder disorder 18.63 11.18 31 33495 19309 79691553
Blood alkaline phosphatase increased 18.58 11.18 64 33462 63600 79647262
Musculoskeletal stiffness 18.56 11.18 28 33498 174980 79535882
Psoriatic arthropathy 18.40 11.18 5 33521 77994 79632868
Biliary dyskinesia 18.08 11.18 12 33514 2533 79708329
External ear cellulitis 17.69 11.18 6 33520 275 79710587
Vascular rupture 17.18 11.18 10 33516 1675 79709187
Brugada syndrome 17.17 11.18 9 33517 1229 79709633
Rheumatoid arthritis 17.10 11.18 39 33487 208431 79502431
Chronic sinusitis 16.94 11.18 24 33502 13002 79697860
Hiatus hernia 16.87 11.18 33 33493 23279 79687583
Hepatic enzyme increased 16.80 11.18 32 33494 182578 79528284
Paranoia 15.92 11.18 29 33497 19403 79691459
Therapeutic product effect decreased 15.71 11.18 28 33498 163835 79547027
Gastric haemorrhage 15.68 11.18 25 33501 15025 79695837
Helicobacter infection 15.47 11.18 5 33521 69699 79641163
Product use in unapproved indication 15.26 11.18 54 33472 250305 79460557
Blood potassium decreased 14.67 11.18 48 33478 46464 79664398
Cellulitis 14.60 11.18 87 33439 108973 79601889
Pneumonia 14.34 11.18 371 33155 659875 79050987
Urinary tract infection 14.16 11.18 177 33349 274335 79436527
Folliculitis 14.14 11.18 3 33523 55377 79655485
Genotype drug resistance test positive 13.97 11.18 8 33518 1300 79709562
Short-bowel syndrome 13.57 11.18 6 33520 563 79710299
Lymphocytosis 13.49 11.18 13 33513 4680 79706182
Asthma-chronic obstructive pulmonary disease overlap syndrome 13.40 11.18 11 33515 3210 79707652
Movement disorder 13.37 11.18 33 33493 27226 79683636
Resorption bone increased 13.08 11.18 8 33518 1467 79709395
Upper respiratory tract infection 13.03 11.18 74 33452 91094 79619768
Ocular neoplasm 12.99 11.18 5 33521 330 79710532
Faeces discoloured 12.97 11.18 34 33492 29093 79681769
Colitis ulcerative 12.95 11.18 38 33488 34704 79676158
Drug interaction 12.91 11.18 112 33414 415071 79295791
Suture insertion 12.87 11.18 5 33521 338 79710524
Melaena 12.67 11.18 55 33471 60835 79650027
Thiopurine methyltransferase decreased 12.56 11.18 5 33521 361 79710501
Lactic acidosis 12.50 11.18 7 33519 70352 79640510
Limb mass 12.34 11.18 11 33515 3588 79707274
Gastric ulcer haemorrhage 12.29 11.18 17 33509 9010 79701852
Skin infection 12.21 11.18 25 33501 18220 79692642
Anaemia 12.08 11.18 258 33268 444757 79266105
Hypersensitivity 12.03 11.18 63 33463 262176 79448686
Wound 11.92 11.18 19 33507 116160 79594702
Upper gastrointestinal haemorrhage 11.55 11.18 41 33485 41339 79669523
Vestibular disorder 11.52 11.18 9 33517 2446 79708416
Gastroenteritis 11.50 11.18 36 33490 34046 79676816
Gastrointestinal ulcer haemorrhage 11.43 11.18 7 33519 1286 79709576
COVID-19 treatment 11.35 11.18 5 33521 465 79710397
Blood loss anaemia 11.29 11.18 22 33504 15476 79695386
Gastric disorder 11.24 11.18 38 33488 37395 79673467

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02BX02 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
FDA CS M0015420 Organometallic Compounds
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D005765 Gastrointestinal Agents
FDA EPC N0000175801 Aluminum Complex

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Duodenal ulcer disease indication 51868009 DOID:1724
Maintenance of Healing Duodenal Ulcer indication
Gingivostomatitis off-label use 20607006
Peptic reflux disease off-label use 57643001
Stomatitis off-label use 61170000 DOID:9637
Gastroesophageal reflux disease off-label use 235595009 DOID:8534
Gastric ulcer off-label use 397825006 DOID:10808
NSAID-Induced Duodenal Ulcer off-label use
Sclerotherapy Induced Esophageal Ulcer off-label use
Stress-Related GI Mucosal Bleeding Prevention off-label use
Maintenance of Healing Gastric Ulcer off-label use
Prevention of Stress Ulcer off-label use
Sclerotherapy-Induced Mucositis off-label use
End stage renal disease contraindication 46177005 DOID:784
Hyperglycemia contraindication 80394007 DOID:4195
Aluminum intoxication contraindication 236546003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Pepsin A-5 Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4018816 VUID
N0000147119 NUI
4018816 VANDF
C0038633 UMLSCUI
CHEBI:9313 CHEBI
CHEMBL3989780 ChEMBL_ID
CHEMBL2367706 ChEMBL_ID
D013392 MESH_DESCRIPTOR_UI
DB00364 DRUGBANK_ID
7055 IUPHAR_LIGAND_ID
2723 INN_ID
XX73205DH5 UNII
10156 RXNORM
1948 MMSL
476 MMSL
5518 MMSL
d00377 MMSL
001132 NDDF
387387008 SNOMEDCT_US
69967001 SNOMEDCT_US
121494085 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-2210 TABLET 1 g ORAL ANDA 20 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-2210 TABLET 1 g ORAL ANDA 20 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 0121-0747 SUSPENSION 1 g ORAL NDA 20 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 0121-0974 SUSPENSION 1 g ORAL ANDA 17 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 0121-0974 SUSPENSION 1 g ORAL ANDA 17 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 0254-1011 SUSPENSION 1 g ORAL NDA authorized generic 19 sections
sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 0378-9205 SUSPENSION 1 g ORAL ANDA 20 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 0615-4517 TABLET 1 g ORAL ANDA 20 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7269 SUSPENSION 1 g ORAL ANDA 17 sections
SUCRALFATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-523 TABLET 1 g ORAL ANDA 2 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 17856-0062 SUSPENSION 1 g ORAL ANDA 18 sections
Carafate HUMAN PRESCRIPTION DRUG LABEL 1 17856-0170 SUSPENSION 1 g ORAL NDA 19 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 17856-0306 SUSPENSION 1 g ORAL ANDA 17 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 17856-1011 SUSPENSION 1 g ORAL NDA AUTHORIZED GENERIC 19 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 17856-1011 SUSPENSION 1 g ORAL NDA AUTHORIZED GENERIC 19 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 29033-003 TABLET 1 g ORAL ANDA 18 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 42291-757 TABLET 1 g ORAL ANDA 20 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 42291-781 SUSPENSION 1 g ORAL ANDA 18 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 42291-781 SUSPENSION 1 g ORAL ANDA 18 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 43353-061 TABLET 1 g ORAL NDA 18 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0582 TABLET 1 g ORAL ANDA 20 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 50090-3019 TABLET 1 g ORAL ANDA 20 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 50090-5287 TABLET 1 g ORAL NDA AUTHORIZED GENERIC 18 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 50090-5287 TABLET 1 g ORAL NDA AUTHORIZED GENERIC 18 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 50090-6455 TABLET 1 g ORAL ANDA 18 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 50268-732 SUSPENSION 1 g ORAL ANDA 18 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 50268-745 SUSPENSION 1 g ORAL ANDA 18 sections
Sucralfate HUMAN PRESCRIPTION DRUG LABEL 1 51079-753 TABLET 1 g ORAL ANDA 20 sections
SUCRALFATE HUMAN PRESCRIPTION DRUG LABEL 1 51655-031 TABLET 1 g ORAL ANDA 20 sections
SUCRALFATE HUMAN PRESCRIPTION DRUG LABEL 1 51655-031 TABLET 1 g ORAL ANDA 20 sections